Can The Medicines Company Rebound From A Phase III Blow?
This article was originally published in The Pink Sheet Daily
Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.
You may also be interested in...
The Medicines Company seemed positive about the prospects for approval of its anti-clotting drug, even though an advisory committee voted against approval just a week ago.
After a brutal panel review, The Medicines Co.’s best chance for its anti-clotting medication may be to create a “better sense of the unmet need” in the perioperative setting when Plavix use must be suspended.
The Medicines Co.’s anti-clotting drug had one relatively positive study, but two failed ones, and that produced two lopsided “no” votes by the Cardiovascular and Renal Drugs Advisory Committee.